Capital Stock Activity (Details Textual) (USD $)	1 Months Ended	3 Months Ended				1 Months Ended		3 Months Ended	1 Months Ended	3 Months Ended		1 Months Ended		3 Months Ended	1 Months Ended		3 Months Ended	1 Months Ended				1 Months Ended	3 Months Ended		1 Months Ended		1 Months Ended	3 Months Ended	1 Months Ended			3 Months Ended	1 Months Ended		3 Months Ended								3 Months Ended					3 Months Ended				3 Months Ended				3 Months Ended				3 Months Ended					3 Months Ended					3 Months Ended					3 Months Ended					3 Months Ended					3 Months Ended
	Feb. 28, 2013	Mar. 31, 2013	Feb. 19, 2013	Dec. 31, 2012	Mar. 31, 2013 Subsequent Event [Member]	Feb. 28, 2013 Lincoln Park [Member]	Feb. 18, 2013 Lincoln Park [Member]	Mar. 31, 2013 Lincoln Park [Member] Subsequent Event [Member]	Apr. 30, 2011 Jp Nevada Trust Note [Member]	Mar. 31, 2013 Jp Nevada Trust Note [Member]	Feb. 19, 2013 Jp Nevada Trust Note [Member]	Feb. 28, 2013 Jp Nevada Trust Note [Member] Criteria One [Member]	Apr. 30, 2011 Jp Nevada Trust Note [Member] Criteria One [Member]	Mar. 31, 2013 Jp Nevada Trust Note [Member] Criteria One [Member]	Feb. 28, 2013 Jp Nevada Trust Note [Member] Criteria Two [Member]	Apr. 30, 2011 Jp Nevada Trust Note [Member] Criteria Two [Member]	Mar. 31, 2013 Jp Nevada Trust Note [Member] Subsequent Event [Member] Criteria Two [Member]	Apr. 30, 2011 Jorden [Member] Criteria One [Member]	Apr. 30, 2011 Jorden [Member] Criteria Two [Member]	Feb. 28, 2013 Burrill Securities Llc [Member]	Feb. 19, 2013 Burrill Securities Llc [Member]	Feb. 28, 2013 Worden [Member]	Mar. 31, 2013 Worden [Member]	Feb. 19, 2013 Worden [Member]	Feb. 28, 2013 Jmj Note [Member]	Feb. 19, 2013 Jmj Note [Member]	Feb. 28, 2013 Midcap Financial Llc [Member]	Mar. 31, 2013 Midcap Financial Llc [Member]	Feb. 28, 2013 Midcap Financial Llc [Member] First Tranche [Member]	Feb. 28, 2013 Midcap Financial Llc [Member] Second Tranche [Member]	Mar. 31, 2013 Midcap Financial Llc [Member] Subsequent Event [Member]	Mar. 31, 2013 Acquisition Of Aldagen [Member]	Feb. 28, 2013 Minimum [Member] Worden [Member]	Feb. 28, 2013 Maximum [Member] Worden [Member]	Mar. 31, 2013 Fitch Coleman Warrants [Member]	Mar. 31, 2013 Fitch Coleman Warrants [Member] Group A Category [Member]	Mar. 31, 2013 Fitch Coleman Warrants [Member] Group B Category [Member]	Mar. 31, 2013 Fitch Coleman Warrants [Member] Group C Category [Member]	Mar. 31, 2013 August 2009 Warrants [Member]		Dec. 31, 2012 August 2009 Warrants [Member]		Mar. 31, 2013 April 2010 Warrant [Member]	Mar. 31, 2013 October 2010 Warrants [Member]		Dec. 31, 2012 October 2010 Warrants [Member]		Mar. 31, 2013 Guarantor 2011 Warrants [Member]		Dec. 31, 2012 Guarantor 2011 Warrants [Member]		Mar. 31, 2013 February 2012 Inducement Warrants [Member]		Dec. 31, 2012 February 2012 Inducement Warrants [Member]		Mar. 31, 2013 Other Warrants [Member]		Dec. 31, 2012 Other Warrants [Member]		Mar. 31, 2013 February 2012 Aldagen Warrants [Member]		Dec. 31, 2012 February 2012 Aldagen Warrants [Member]		Mar. 31, 2013 August 2010 Warrants [Member]	Mar. 31, 2013 February 2013 MidCap Warrants (Member)		Feb. 28, 2013 February 2013 MidCap Warrants (Member)	Dec. 31, 2012 February 2013 MidCap Warrants (Member)		Mar. 31, 2013 February 2013 Subordination Warrants (Member)		Feb. 28, 2013 February 2013 Subordination Warrants (Member)	Dec. 31, 2012 February 2013 Subordination Warrants (Member)		Mar. 31, 2013 February 2013 Worden Warrants [Member]		Feb. 28, 2013 February 2013 Worden Warrants [Member]	Dec. 31, 2012 February 2013 Worden Warrants [Member]		Mar. 31, 2013 February 2013 RDO Warrants [Member]		Feb. 28, 2013 February 2013 RDO Warrants [Member]	Dec. 31, 2012 February 2013 RDO Warrants [Member]		Mar. 31, 2013 February 2013 PA Warrants [Member]		Feb. 28, 2013 February 2013 PA Warrants [Member]	Dec. 31, 2012 February 2013 PA Warrants [Member]
Total new shares issued		10,528,991
Class Of Warrant Or Right Exercise Term																																			7 years 6 months
Class Of Warrant Or Right Outstanding																																				325,000	325,000	325,000	1,070,916	[1]	1,070,916	[1]		1,488,839	[2]	1,488,839	[2]	916,665	[3]	916,665	[3]	1,180,547	[4]	1,180,547	[4]	200,000	[5]	200,000	[5]	2,115,596	[6]	2,115,596	[6]		1,079,137	[7]		0	[7]	800,000	[8]		0	[8]	250,000	[9]		0	[9]	6,363,638	[10]		0	[10]	136,364	[11]		0	[11]
Entire Outstanding Warrants Callup Condition Based On Minimum Trading Price																																				$ 4	$ 5	$ 6
Class Of Warrant Or Righst Date From Which Warrants Or Rights Expiration																																											Apr. 09, 2015	Apr. 07, 2016				Apr. 28, 2016				Dec. 31, 2014				Feb. 24, 2014				Dec. 31, 2014					Feb. 19, 2020					Apr. 28, 2015					Feb. 19, 2020					Feb. 22, 2018					Feb. 22, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		303,000
Share Based Compensation Arrangement By Share Based Payment Award Stock Options and Compensatory Warrants Forfeited In Period		7,001
Additional Warrants Adjustments Due To Antidilutive Provisions																																							420,896
Common Stock Capital Shares Reserved For Future Issuance Value						$ 15,000,000		$ 15,000,000
Shares Issuable Under Purchase Agreements						150,000
Increase In Shares Issuable Under Purchase Agreements						200,000
Sale of Stock, Price Per Share							$ 1.00
Stock Issued During Period Share Purchase Agreement						375,000
Stock Issued During Period Additonal Shares Issued Under Purcahse Agreement	375,000
Proceeds from Issuance of Private Placement	5,000,000																															5,000,000
Share Price			$ 0.55
Warrants Exercise Price			$ 0.75		$ 0.75
Placement Fee																				350,000
Expense Reimbursement Limit																				52,000
Warrant Exercise Price Percentage																				120.00%
Term Loan Commitments																												7,500,000
Conditions For Obtaining Second Tranche Receipts Criteria Two																												(ii) raises an amount of not less than $5.0 million in the aggregate from (a) equity investors, and/or (b) partnership proceeds on or before July 31, 2013 (the "Capital Raise Event").
Conditions For Obtaining Second Tranche Receipts Creteria 1																												(i) if the Company achieves certain performance milestones for 2013.
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			6,363,637						533,334	266,666											136,364			250,000				1,079,137			1,079,137
Class of Warrant or Right, Exercise Price of Warrants or Rights										0.70														0.7				0.7			0.70					1.25	1.5	1.75	0.51				0.54	0.60				0.50				1.42								1.42				0.50			0.70					0.70					0.70					0.75					0.66
Debt Instrument Descirption Of Floor Price		LIBOR floor of 3																										LIBOR floor of 3%.
Term Loan Fee Payable Percentage Year One		5.00%																										5.00%
Term Loan Fee Payable Percentage Year Two		3.00%																										3.00%
Term Loan Fee Payable Percentage Thereafter		1.00%																										1.00%
Royalty Expense																						5,000,000	500,000
Future Annaul Royalty Limitation																																	600,000	625,000
Warrants Exercisable									500,000	250,000
Warrants Exercised Upon Default In Payment Of Note On Fourth Anniversary												133,333	266,667	133,333			133,333	57,143
Guarantor Obligations, Current Carrying Value										1,400,000
Warrants Exercised Upon Default In Payment Of Note On Fifth Anniversary									107,143						133,333	266,667			57,143
Note payable		6,045,208		2,100,000							2,100,000															100,000
Long-term Debt, Gross																										750,000
Condition For Accelerated Purchase By Accredited Investor Minimum Share Price						0.45
Shares Issued In Private Placement Maximum Percentage						9.99%
Debt Instrument Remitted Payment																									370,000
Debt Instrument, Description of Variable Rate Basis																												(LIBOR) plus 8.0%.
Proceeds From Term Loan Commitments																											$ 4,500,000		$ 4,500,000	$ 3,000,000
Stock Issued During Period Shares Investors	9,090,910

[1] These warrants were issued in connection with the August 2009 financing, are voluntarily exercisable at $0.51 per share and expire in February 2014. These amounts reflect adjustments for an additional 420,896 warrants due to anti-dilutive provisions. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.

[2] These warrants were issued in connection with the October 2010 financing. They have an exercise price of $0.60 and expire on April 7, 2016. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.

[3] These warrants were issued pursuant to the Guaranty Agreements executed in connection with the Promissory Note issued in April 2011. These warrants have an exercise price of $0.50 per share and expire on April 28, 2016.

[4] These warrants were issued in connection with the February 2012 warrant exercise agreements executed with certain existing Cytomedix warrant holders. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.

[5] These warrants were issued to a consultant in exchange for services provided. They are voluntarily exercisable, have an exercise price of $1.50 per share, and expire on February 24, 2014. There is no call provision associated with these warrants.

[6] These warrants were issued in February 2012 in connection with the warrant exchange agreements between Cytomedix and various warrant holders of Aldagen. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.

[7] These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share and expire on February 19, 2020.

[8] These warrants were issued in connection with the February 2013 financing, have an exercise price of $0.70 per share, and expire on February 19, 2018. They are only exercisable if the JPNT Note remains outstanding on or after 04-28-2015 (50% of total) and 04-15-2016 (remainder).

[9] These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share, and expire on February 19, 2020.

[10] These warrants were issued in connection with the February 2013 registered direct offering. They are voluntarily exercisable, have an exercise price of $0.75 per share, and expire on February 22, 2018.

[11] These warrants were issued to the placement agent in connection with the February 2013 registered direct offering. They are exercisable on or after August 21, 2013, have an exercise price of $0.66 per share, and expire on February 22, 2018.